Protective effect of astragalosides from Radix Astragali on adriamycin-induced podocyte injury Corrigendum in /10.3892/etm.2018.6361

Sai,Yi‑Pa; Song,Yuan‑Chun; Chen,Xing‑Xing; Luo,Xuan; Liu,Jing; Cui,Wei‑Jing

doi:10.3892/etm.2018.5933

Protective effect of astragalosides from Radix Astragali on adriamycin-induced podocyte injury

Corrigendum in: /10.3892/etm.2018.6361

Authors:
- Yi‑Pa Sai
- Yuan‑Chun Song
- Xing‑Xing Chen
- Xuan Luo
- Jing Liu
- Wei‑Jing Cui
View Affiliations

Affiliations: Department of Pediatrics, Gansu Province People's Hospital, Lanzhou, Gansu 730000, P.R. China
Published online on: March 6, 2018 https://doi.org/10.3892/etm.2018.5933
Pages: 4485-4490

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nephrotic syndrome (NS) is the most common kidney disease in clinical practice and may lead to end‑stage renal failure. Astragalosides (AST) have been clinically tested for the treatment of NS, but their mechanism of action has remained to be elucidated. The aim of the present study was to investigate the effect of AST on the structure and function of podocytes with adriamycin (ADR)‑induced damage and to elucidate the underlying molecular mechanisms. The mouse podocyte clone 5 (MPC5) immortalized mouse podocyte cell line was treated with 0.5 µmol/l ADR to establish a podocyte injury model. The MPC5 podocytes were divided into a control group, a podocyte injury group and a low‑, medium‑ and high-concentration AST treatment group. The results indicated that the survival rate of the podocyte injury group was significantly decreased compared with that in the control group and each AST‑treated group had an increased survival rate compared with that in the podocyte injury group. Furthermore, each dose of AST significantly inhibited the ADR-associated increases the levels of lactate dehydrogenase and malondialdehyde and the decrease in the activity of superoxide dismutase in MPC5 podocytes. In addition, AST improved the migration ability of MPC5 podocytes and suppressed the cytoskeletal rearrangement associated with ADR‑induced damage. Furthermore, matrix metalloproteinase (MMP)-2 and ‑9 were decreased in the podocyte injury group, which was inhibited by different concentrations of AST. Thus, AST was able to maintain the balance of oxidative stress in podocytes cultured with ADR and protect them from ADR-induced injury. The mechanism may be associated with the upregulation of MMPs.

View Figures

View References

1	Pavenstadt H, Kriz W and Kretzler M: Cell biology of the glomerular podocyte. Physiol Rev. 83:253–307. 2003. View Article : Google Scholar : PubMed/NCBI
2	Shankland SJ and Al'Douahji M: Cell cycle regulatory proteins in glomerular disease. Exp Nephrol. 7:207–211. 1999. View Article : Google Scholar : PubMed/NCBI
3	Zhu C, Xuan X, Che R, Ding G, Zhao M, Bai M, Jia Z, Huang S and Zhang A: Dysfunction of the PGC-1α-mitochondria axis confers adriamycin-induced podocyte injury. Am J Physiol Renal Physiol. 306:F1410–F1417. 2014. View Article : Google Scholar : PubMed/NCBI
4	Maezawa Y, Onay T, Scott RP, Keir LS, Dimke H, Li C, Eremina V, Maezawa Y, Jeansson M, Shan J, et al: Loss of the podocyte expressed transcription factor Tcf21/Pod1 results in podocyte differentiation defects and FSGS. J Am Soc Nephrol. 25:2459–2470. 2014. View Article : Google Scholar : PubMed/NCBI
5	Hanamura K, Tojo A and Fujita T: Urinary and glomerular podocytes in patients with chronic kidney diseases. Clin Exp Nephrol. 18:95–103. 2014. View Article : Google Scholar : PubMed/NCBI
6	Takeda A, Ohgushi H, Niimura F and Matsutani H: Long-term effects of immunosuppressants in steroid-dependent nephrotic syndrome. Pediatr Nephrol. 12:746–750. 1998. View Article : Google Scholar : PubMed/NCBI
7	Hogan J and Radhakrishnan J: The treatment of minimal change disease in adults. J Am Soc Nephrol. 24:702–711. 2013. View Article : Google Scholar : PubMed/NCBI
8	Shahzad M, Shabbir A, Wojcikowski K, Wohlmuth H and Gobe GC: The Antioxidant effects of radix astragali (astragalus membranaceus and related species) in protecting tissues from injury and disease. Curr Drug Targets. 17:1331–1340. 2016. View Article : Google Scholar : PubMed/NCBI
9	Liu G, Song J, Guo Y, Wang T and Zhou Z: Astragalus injection protects cerebral ischemic injury by inhibiting neuronal apoptosis and the expression of JNK3 after cerebral ischemic reperfusion in rats. Behav Brain Funct. 9:362013. View Article : Google Scholar : PubMed/NCBI
10	Feng M, Yuan W, Zhang R, Fu P and Wu T: Chinese herbal medicine Huangqi type formulations for nephrotic syndrome. Cochrane Database Syst Rev. 6:Cd0063352013.
11	Korbet SM: Treatment of primary FSGS in adults. J Am Soc Nephrol. 23:1769–1776. 2012. View Article : Google Scholar : PubMed/NCBI
12	Yuan W, Wang J and Wu T: Chinese herbal medicine Huangqi type formulations for nephrotic syndrome. Cochrane Database Syst Rev. 2:Cd0063352008.
13	Xu M, Yin J, Xie L, Zhang J, Zou C, Zou J, Liu F, Ju W and Li P: Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers. Phytomedicine. 20:1105–1111. 2013. View Article : Google Scholar : PubMed/NCBI
14	Wang N, Wei RB, Li QP, Yang X and Chen X: Protective effects of astragaloside in rats with adriamycin nephropathy and underlying mechanism. Chin J Nat Med. 14:270–277. 2016.PubMed/NCBI
15	Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thoua Y, Mecca G, Remuzzi G and Donati MB: Adriamycin-induced nephrotic syndrome in rats: Sequence of pathologic events. Lab Invest. 46:16–23. 1982.PubMed/NCBI
16	Yi M, Zhang L, Liu Y, Livingston MJ, Chen JK, Nahman NS Jr, Liu F and Dong Z: Autophagy is activated to protect against podocyte injury in adriamycin-induced nephropathy. Am J Physiol Renal Physiol. 313:F74–F84. 2017. View Article : Google Scholar : PubMed/NCBI
17	Saito Y, Okamura M, Nakajima S, Hayakawa K, Huang T, Yao J and Kitamura M: Suppression of nephrin expression by TNF-alpha via interfering with the cAMP-retinoic acid receptor pathway. Am J Physiol Renal Physiol. 298:1436–1444. 2010. View Article : Google Scholar
18	Zhang HT, Wang WW, Ren LH, Zhao XX, Wang ZH, Zhuang DL and Bai YN: The mTORC2/Akt/NFκB pathway-mediated activation of TRPC6 participates in adriamycin-induced podocyte apoptosis. Cell Physiol Biochem. 40:1079–1093. 2016. View Article : Google Scholar : PubMed/NCBI
19	Wang N, Wei RB, Li P, Li QP, Yang X, Yang Y, Huang MJ, Wang R, Yin Z, Lv Y and Chen XM: Treatment with irbesatan may improve slit diaphragm alterations in rats with adriamycin-inducednephropathy. J Renin Angiotensin Aldosterone Syst. 17:14703203166468842016. View Article : Google Scholar : PubMed/NCBI
20	Susztak K, Raff AC, Schiffer M and Böttinger EP: Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 55:225–233. 2006. View Article : Google Scholar : PubMed/NCBI
21	Asanuma K, Yanagida-Asanuma E, Faul C, Tomino Y, Kim K and Mundel P: Synaptopodin orchestrates actin organization and cell motility via regulation of RhoA signaling. Nat Cell Biol. 8:485–491. 2006. View Article : Google Scholar : PubMed/NCBI
22	Lei FY, Zhou TB, Qin YH, Chen XP and Li ZY: Potential signal pathway of all-trans retinoic acid for MMP-2 and MMP-9 expression in injury podocyte induced by adriamycin. J Recept Signal Transduct Res. 34:378–385. 2014. View Article : Google Scholar : PubMed/NCBI
23	Merkle M, Ribeiro A, Köppel S and Wörnle M: TNF-α enhances TLR3-dependent effects on MMP-9 expression in human mesangial cells. Cell Biol Int. 36:1155–1160. 2012. View Article : Google Scholar : PubMed/NCBI